At the heart of every healthcare system, lies a simple truth: behind every therapy, every reform, every decision, there is a person. Someone hoping for more time, more answers, more life. And while innovation may begin in laboratories across the world, its real purpose is fulfilled only when it reaches the patients.
At Medison, this purpose guides every step we take. Through our Global Partnership model, we ensure that innovative therapies in rare and severe diseases, reach patients faster across most of the World. In countries like Greece, this model translates into tangible impact: patients gain timely access to innovative therapies that can redefine their journeys. Physicians expand their therapeutic options. Families reclaim precious moments. What we see locally is very much part of a broader, global effect, one where innovation does not stop at borders.
Yet sustaining this impact requires a system that does not allow innovation to stall. While scientific advances accelerate, access pathways must evolve at the same pace. Greece, like many countries, needs timely decisions, modern evaluation frameworks and sustainable funding models that reflect both the urgency of patients’ needs and the realities of biotech innovation.
Medison’s, “We Care” approach aligns seamlessly with the PhARMA Innovation Forum and the Voices of Innovation initiative, which highlights the societal and clinical impact of biotech innovation. They reinforce a simple truth: progress is meaningful only when patients can access it. In Greece and beyond, patients should not have to wait for the promise of innovative therapies. Access must happen when it matters most.
Yvoni Papastelatou, Country Manager Greece, Cyprus & Malta
